Persistence and improvement of nasolabial fold correction with nonanimal-stabilized hyaluronic acid 100,000 gel particles/mL filler on two retreatment schedules: results up to 18 months on two retreatment schedules.
BACKGROUND
Nonanimal-stabilized hyaluronic acid (NASHA) fillers are frequently used for facial soft tissue augmentation. Their long-term efficacy and the effects of different retreatment schedules are not well established.


OBJECTIVE
This is an 18-month interim analysis of a 30-month study to evaluate the efficacy and persistence of NASHA 100,000 gel particles/mL filler with two different retreatment schedules.


METHODS
This multicenter, randomized, evaluator-blinded study enrolled 75 patients with moderate to severe nasolabial folds. Patients were randomized to retreatment of one nasolabial fold at 4.5 months and the contralateral fold at 9 months after correction of both folds at the initial visit.


RESULTS
Wrinkle Severity Rating Scale scores improved significantly (p<.001) from baseline, with mean improvements ranging from 1.1 to 1.7 grades. Almost all patients (97%) responded satisfactorily, and the efficacy of the retreatment schedules did not differ significantly. Adverse events, primarily swelling and bruising, occurred in 33% of patients; none were serious.


CONCLUSIONS
The improvements seen after initial treatment with NASHA 100,000 gel particles/mL filler persisted for up to 18 months with one retreatment. The response was equivalent for retreatment at 4.5 and 9 months.
Narins
Rhoda S
RS
Dermatology Surgery and Laser Center of New York and New York University Medical Center, New York, New York 10604, USA. rsnmd@att.net
Dayan
Steven H
SH
Brandt
Frederic S
FS
Baldwin
Edward K
EK
D000328:Adult; D000368:Aged; D000704:Analysis of Variance; D001672:Biocompatible Materials / Q000008:administration & dosage* / Q000009:adverse effects; D003357:Cosmetic Techniques / Q000009:adverse effects; D004334:Drug Administration Schedule; D005145:Face; D005260:Female; D005782:Gels; D006801:Humans; D006820:Hyaluronic Acid / Q000008:administration & dosage / Q000009:adverse effects / Q000031:analogs & derivatives*; D007271:Injections, Intradermal; D008297:Male; D008875:Middle Aged; D019233:Retreatment; D016037:Single-Blind Method; D015595:Skin Aging; D013997:Time Factors; D016896:Treatment Outcome
D001672:Biocompatible Materials; D005782:Gels; D006820:Hyaluronic Acid; C445361:Restylane